Coronavirus Disease 2019(COVID-19)is caused by severe acute respiratory syndrome coronavirus 2(SARS-CoV-2).Patients with B-cell lymphoma may experience immunodeficiency due to the disease itself and its treatment,making them a high-risk group for susceptibility and severe out-comes of COVID-19.Therefore,it is crucial to analyze the baseline characteristics of B-cell non-Hodgkin lymphoma patients diagnosed with COVID-19,investigate common risk factors,evaluate the efficacy of vaccination and assess the immune deficiencies induced by immunotherapy,particularly CD20 monoclonal antibodies.For B-cell NHL patients with COVID-19,an individualized assessment of risk factors is necessary.This review discussed the immune response of lymphoma patients to COVID-19,summarized the characteristics of lymphoma patients following COVID-19,analyzed the vaccine effectiveness in this population,and explored the impact of COVID-19 on the onset and anti-tumor treatment of B-cell non-Hodgkin lymphoma,along with associated risk factors,aiming to provide recommendations for formulating treatment strategies and clinical management.

Coronavirus Disease 2019(COVID-19)is caused by severe acute respiratory syndrome coronavirus 2(SARS-CoV-2).Patients with B-cell lymphoma may experience immunodeficiency due to the disease itself and its treatment,making them a high-risk group for susceptibility and severe out-comes of COVID-19.Therefore,it is crucial to analyze the baseline characteristics of B-cell non-Hodgkin lymphoma patients diagnosed with COVID-19,investigate common risk factors,evaluate the efficacy of vaccination and assess the immune deficiencies induced by immunotherapy,particularly CD20 monoclonal antibodies.For B-cell NHL patients with COVID-19,an individualized assessment of risk factors is necessary.This review discussed the immune response of lymphoma patients to COVID-19,summarized the characteristics of lymphoma patients following COVID-19,analyzed the vaccine effectiveness in this population,and explored the impact of COVID-19 on the onset and anti-tumor treatment of B-cell non-Hodgkin lymphoma,along with associated risk factors,aiming to provide recommendations for formulating treatment strategies and clinical management.